Rare diseases
Investigational molecules
Locations
Recruiting trials first
27 clinical trials in this condition
Belgium
Germany
AustriaGermanyIn short
Living with Sjögren's syndrome means learning how to manage persistent dryness throughout your body, but with the right combination of treatments and daily care strategies, many people continue to lead active, fulfilling lives despite this challenging autoimmune condition.
When someone receives a diagnosis of Sjögren's syndrome, the first question that often comes to mind is: what can be done to feel better? The treatment journey for this condition is deeply personal, as each patient experiences different symptoms with varying levels of severity. The main goal of treatment is not to cure the disease—because currently no cure exists—but rather to help manage symptoms, prevent complications, and improve quality of life. This means working closely with healthcare providers to find a tailored plan that addresses your specific challenges, whether that's extreme dryness, fatigue, joint pain, or organ involvement.
Treatment approaches for Sjögren's syndrome depend heavily on which parts of your body are affected and how severe your symptoms are. Some people experience only mild discomfort and can manage with over-the-counter products and lifestyle adjustments. Others face debilitating symptoms that greatly impair their daily functioning and require prescription medications or more intensive interventions. Because Sjögren's is a systemic disease that can affect the entire body, your healthcare team may include several specialists—a rheumatologist to coordinate overall care, an ophthalmologist for eye concerns, a dentist for oral health, and possibly others depending on which organs are involved.
The good news is that medical societies have developed standard treatment recommendations based on years of research, and at the same time, scientists continue to explore new therapies through clinical trials. This means that patients today have access to proven treatments while researchers work on developing even better options for the future.
The foundation of treating Sjögren's syndrome starts with addressing the most common and bothersome symptom: dryness. For dry eyes, many patients begin with artificial tears—lubricating eye drops that can be purchased without a prescription. These drops temporarily replace natural tears and should be used throughout the day to prevent discomfort and protect the surface of the eye. It's important to choose preservative-free formulations, especially if you need to use drops frequently, because preservatives can irritate already sensitive eyes.
When over-the-counter artificial tears aren't enough, doctors may prescribe special eye drops that do more than just add moisture—they actually help your eyes produce more natural tears. Two medications commonly prescribed for this purpose are cyclosporine (brand name Restasis) and lifitegrast (brand name Xiidra). These prescription eye drops work by reducing inflammation on the surface of the eye, which allows the tear glands to function better. Patients typically need to use these drops twice daily, and it may take several weeks before you notice improvement. Some people experience a burning sensation when first using cyclosporine drops, but this side effect often lessens over time.
For dry mouth, the treatment strategy is similar—starting simple and advancing to prescription medications if needed. Sipping water throughout the day, chewing sugar-free gum, and sucking on sugar-free hard candies can all help stimulate saliva production. However, when these measures aren't sufficient, doctors may prescribe medications that directly stimulate the salivary glands. The two main drugs used for this purpose are pilocarpine (brand name Salagen) and cevimeline (brand name Evoxac). These medications cause the salivary glands to produce more saliva by acting on certain receptors in the glands. Common side effects can include sweating, flushing, and increased need to urinate, because these drugs affect similar receptors throughout the body.
Joint pain and muscle aches are common in Sjögren's syndrome, affecting many patients beyond the signature dryness symptoms. For these concerns, doctors often recommend nonsteroidal anti-inflammatory drugs or NSAIDs. These medications reduce inflammation and pain by blocking the production of prostaglandins—chemicals in the body that promote inflammation and cause pain. Common over-the-counter NSAIDs include aspirin, ibuprofen (Advil, Motrin), and naproxen (Aleve). Many prescription-strength NSAIDs are also available. The most common side effect is stomach upset, and in rare cases, NSAIDs can cause stomach bleeding. Taking these medications with food or milk can help reduce stomach irritation.
When Sjögren's syndrome causes more serious systemic problems—affecting internal organs like the lungs, kidneys, or nervous system, or when joint pain and fatigue become severe—stronger medications may be necessary. Hydroxychloroquine is a medication originally developed to treat malaria but now commonly used for autoimmune conditions. It helps reduce inflammation throughout the body and may help with fatigue and joint pain. This medication must be taken daily for several months before its full benefits are seen.
For more severe cases, doctors may prescribe medications that more powerfully suppress the immune system. These include corticosteroids (such as prednisone), which quickly reduce inflammation but can have significant side effects if used long-term, including weight gain, increased blood sugar, bone thinning, and increased infection risk. Other immune-suppressing medications used in Sjögren's include methotrexate (Rheumatrex), azathioprine (Imuran), and mycophenolate (Cellcept). These medications are typically reserved for patients with serious organ involvement or symptoms that haven't responded to other treatments.
In life-threatening cases or when major organs are severely affected, a medication called rituximab (Rituxan) may be used. This drug works by targeting and temporarily depleting certain white blood cells called B-lymphocytes, which play a role in the autoimmune attack. Rituximab is given as an intravenous infusion, meaning it's delivered directly into a vein over several hours in a medical facility. For patients with nervous system involvement, intravenous immunoglobulin therapy (IVIG) might provide benefits. This treatment involves infusing antibodies collected from donated blood plasma to help modulate the immune system.
Patients who experience acid reflux—a common problem when you have dry mouth and reduced saliva—may benefit from medications called proton-pump inhibitors or H2 blockers. These medications reduce the amount of acid your stomach produces, helping prevent damage to the esophagus and reducing that unpleasant burning sensation.
Standard treatment typically continues for years, often for a patient's entire life. The duration and intensity of treatment depend on how active the disease is and which symptoms are most troublesome. Regular monitoring by healthcare providers is essential to assess whether treatments are working, to watch for side effects, and to adjust the treatment plan as needed over time.
While standard treatments help many people with Sjögren's syndrome manage their symptoms, researchers recognize that current options don't work for everyone and that better therapies are needed. This has led to growing interest from pharmaceutical companies and research institutions in developing new treatments specifically for this condition. Clinical trials are research studies that test new drugs or therapies to determine whether they are safe and effective. These trials represent hope for patients who haven't found adequate relief with existing treatments.
Clinical trials typically progress through several phases. Phase I trials focus primarily on safety—researchers want to know if the new treatment causes harmful side effects and what dose is appropriate. These studies usually involve small numbers of participants. Phase II trials expand to larger groups and focus on whether the treatment actually works—does it improve symptoms or slow disease progression? Phase III trials compare the new treatment directly against current standard treatments to see if the new option is better, equally effective, or perhaps causes fewer side effects. Only after successfully completing these phases can a new drug be approved by regulatory agencies like the FDA in the United States or similar bodies in other countries.
Several innovative therapies are currently being evaluated in Phase II and Phase III clinical trials for Sjögren's syndrome. One promising drug is called dazodalibep. This medication works by targeting a specific molecular pathway that drives inflammation in autoimmune diseases. Dazodalibep blocks the interaction between two proteins—CD40 and CD40 ligand—that normally work together to activate immune cells. By interrupting this communication, the drug aims to reduce the immune system's attack on moisture-producing glands. Early trial results have shown that patients taking dazodalibep experienced improvements in clinical parameters measuring disease activity, with a favorable safety profile reported in preliminary findings.
Another drug being tested is ianalumab, which represents a different approach to calming the overactive immune system. This medication is a type of monoclonal antibody—a laboratory-made protein designed to attach to specific targets on immune cells. Ianalumab targets a receptor called B-cell activating factor receptor (BAFF-R) found on B-cells, a type of white blood cell that produces antibodies. In Sjögren's syndrome, B-cells play a significant role in the autoimmune attack. By blocking BAFF-R, ianalumab depletes these problematic B-cells, potentially reducing inflammation and symptoms. This drug is administered as an injection and has shown encouraging results in clinical studies.
A third experimental treatment is nipocalimab, another monoclonal antibody that works through yet another mechanism. This drug targets the neonatal Fc receptor (FcRn), which is involved in prolonging the life of antibodies in the bloodstream. By blocking this receptor, nipocalimab helps clear harmful autoantibodies—the antibodies that mistakenly attack the body's own tissues—from the circulation more quickly. This approach could potentially reduce the autoimmune damage that causes Sjögren's symptoms. Clinical trials are evaluating whether this mechanism translates into real benefits for patients.
These clinical trials are being conducted at medical centers throughout the United States, Europe, and other regions around the world. Eligibility to participate varies depending on the specific study but generally includes adults with a confirmed diagnosis of Sjögren's syndrome who meet certain criteria regarding disease severity and symptoms. Some trials specifically seek patients who haven't responded well to standard treatments, while others may be open to people with different levels of disease activity. Participation in a clinical trial is voluntary and involves careful monitoring by the research team. Patients receive the investigational treatment at no cost and often receive compensation for their time and travel.
Beyond these specific drugs, researchers are also exploring other innovative approaches. Some studies are investigating whether targeting different inflammatory pathways or using combination therapies might be more effective than single-drug treatments. The heterogeneity of Sjögren's syndrome—meaning that patients have very different patterns of symptoms and disease involvement—has led scientists to consider whether clustering patients into biologically similar subgroups could improve treatment outcomes. This personalized medicine approach might allow doctors to predict which patients will respond best to which treatments.
While these new therapies are promising, it's important to maintain realistic expectations. Not every drug that enters clinical trials proves to be effective, and even successful drugs may only work for a subset of patients. The clinical trial process typically takes many years from initial testing to final approval, so these investigational treatments may not be widely available for some time. However, the fact that multiple pharmaceutical companies are now investing in Sjögren's syndrome research represents a significant shift—this disease, which has historically received less attention than some other autoimmune conditions, is finally getting the research focus it deserves.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Patient organisations offering help, community and advocacy
Tell us about your condition – we search every trial in Europe and connect you with the right site.
